The effects of renin-angiotensin system inhibition of regression of encapsulation peritoneal sclerosis

Peritoneal Dialysis International

Volumn 28, Issue SUPPL. 5, 2008, Pages

  Bozkurt, Devrim ^a   Cetin, Pinar ^a   Sipahi, Savas ^a   Hur, Ender ^a   Nar, Hasim ^a   Ertilav, Muhittin ^a   Sezak, Murat ^a   Duman, Soner ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Encapsulated peritoneal sclerosis; RAS blockade; Vascularity

Indexed keywords

CHLORHEXIDINE GLUCONATE; ENALAPRIL MALEATE; SODIUM CHLORIDE; UREA; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; CHLORHEXIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; ENALAPRIL; TETRAZOLE DERIVATIVE; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIALYSATE LEVEL; DRUG EFFICACY; ENCAPSULATING PERITONEAL SCLEROSIS; FEMALE; FIBROSIS; INFLAMMATION; LEUKOCYTE COUNT; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PRIORITY JOURNAL; RAT; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REST; THERAPY EFFECT; ULTRAFILTRATION; UREA BLOOD LEVEL; ANIMAL; DISEASE MODEL; PATHOLOGY; PERITONEUM; SCLEROSIS; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CHLORHEXIDINE; DISEASE MODELS, ANIMAL; ENALAPRIL; FEMALE; PERITONEAL DIALYSIS; PERITONEUM; RATS; RATS, WISTAR; SCLEROSIS; TETRAZOLES; VALINE;

EID: 67149133442     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
2. Mateijsen MAM, van der Wal AC, Hendriks PMEM, Zweers MM, Mulder J, Struijk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19:517-25.
3. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005; 25:38-47.
4. Zweers MM, Struijk DG, Smit W, Krediet RT. Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up. J Lab Clin Med 2001; 137:125-32.
5. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22:171-7.
6. Lee HB, Yu MR, Song JS, Ha H. Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by peritoneal mesothelial cells. Kidney Int 2004; 65:1170-9.
7. Vieitez P, Gómez O, Uceda ER, Vera ME, Molina-Holgado E. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 2008; 9:96-102.
8. De Mello WC, Specht P. Chronic blockade of angiotensin II AT1-receptors increased cell-to-cell communication, reduced fibrosis and improved impulse propagation in the failing heart. J Renin Angiotensin Aldosterone Syst 2006; 7:201-5.
9. Müller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F, et al. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol 2000; 157:111-22.
10. Hsieh TJ, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, Chan JS. High glucose stimulates angiotensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology 2002; 143:2975-85.
11. Wong TY, Phillips AO, Witowski J, Topley N. Glucose-mediated induction of TGF-beta 1 and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. Kidney Int 2003; 63:1404-16.
12. Duman S, Gunal AI, Sen S, Asci G, Ozkahya M, Terzioglu E, et al. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 2001; 21:219-24.
13. Duman S, Sen S, Duman C, Oreopoulos DG. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs 2005; 28:156-63.
14. Hoff CM. Experimental animal models of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4): S57-66.
15. Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N. TGF-beta1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int 2005; 25:483-91.
16. Selgas R, Bajo A, Jiménez-Heffernan JA, Sánchez-Tomero JA, Del Peso G, Auilera A, et al. Epithelial-to-mesenchymal transition of the mesothelial cell - its role in the response of the peritoneum to dialysis. Nephrol Dial Transplant 2006; 21(Suppl 2):ii2-7.
17. Ersoy R, Celik A, Yilmaz O, Sarioglu S, Sis B, Akan P, et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int 2007; 27: 424-31.
18. de Alvaro F, Castro MJ, Dapena F, Bajo MA, Fernandez-Reyes MJ, Romero JR, et al. Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial 1993; 9:56-61.
19. Rodrigues A, Cabrita A, Maia P, Guimarães S. Peritoneal rest may successfully recover ultrafiltration in patients who develop peritoneal hyperpermeability with time on continuous ambulatory peritoneal dialysis. Adv Perit Dial 2002; 18:78-80.
20. Zareie M, Keuning ED, ter Wee PM, Beelen RH, van den Born J. Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats. Nephrol Dial Transplant 2005; 20:189-93.
21. Tomo T, Okabe E, Matsuyama K, Iwashita T, Yufu K, Nasu M. The effect of peritoneal rest in combination therapy of peritoneal dialysis and hemodialysis: using the cultured human peritoneal mesothelial cell model. J Artif Organs 2005; 8:125-9.
22. Kawanashi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a randomized controlled multicenter study. Am J Kidney Dis 2004; 44:729-37.